ALBO

Albireo Pharma, Inc. (ALBO) | Rumor.io

Albireo Pharma

ALBO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ALBO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Apr 25

The $ALBO meme coin is now permanent on the Solana blockchain, making it impossible for the Australian PM to censor.
The coin is being used to support the Australian government in their legal battle, with some users donating a portion of their $ALBO holdings to the cause.
The $ALBO meme coin is expected to gain popularity in the next few weeks, with some users predicting it could become a top 10 material.

Generated by AI

Sentiment

Of the messages about ALBO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +20.83
Bearish	—	—	—	0% -20.83

Bullish· Jan 9

The acquisition of Albireo Pharma by Ipsen is a significant event with a potential buyout price of $42 per share, up from its previous closing price.
The buyout has a positive read-through to another company, XFOR, which has recently secured a $30m loan and is now well capitalized, potentially leading to a 3x-5x organic growth and 8x-10x on a buyout.
The Albireo Pharma acquisition is a great example of patience paying off in investing, with long-term holders able to secure a significant profit, and may lead to increased focus on other takeover candidates in the biotech industry.

Bearish· Aug 16

Albireo Pharma's stock price has dropped significantly, from a high of $42 to $18, due to poor commercialization efforts.
The company's sales costs are high, with a sales personnel cost increase of $6 million, and the sales force is inefficient, leading to missed sales targets.
Albireo Pharma's cash burn is a major concern, with a net loss of $40 million and a risk of running out of money in less than 6 months if the current burn rate continues.

Generated by AI

Topics

Of the messages about ALBO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	0%
Macro	—	—	—	0%
Earnings	—	—	—	0%
Controversies	—	—	—	0%
Announcements	—	—	—	100%
Analysts	—	—	—	0%

Earnings· Aug 7

Albireo Pharma, Inc. (ALBO) misses EPS loss estimates by $0.27.
Albireo Pharma, Inc. (ALBO) beats revenue estimates.
Albireo Pharma, Inc. (ALBO) announces earnings with an EPS of $1.22, missing estimates.

Analysts· Jan 11

Analysts have downgraded Albireo Pharma, with Cowen lowering the stock to Market Perform from Outperform and Jefferies downgrading to Hold from Buy.
Price targets have been lowered for Albireo Pharma, with Cowen setting a new target of $48 and Jefferies lowering its target to $42.
Multiple analysts, including those from Cowen, Jefferies, and Guggenheim, have downgraded Albireo Pharma, citing concerns about the company's prospects following Ipsen's proposed acquisition.

Announcements· Jan 10

Albireo Pharma, Inc. (ALBO) agreed to be acquired by Ipsen in a deal valued at $952 million, with shares jumping 92% to a new 52-week high.
The acquisition price of $42.00 per share will be paid in cash, with an additional contingent value right (CVR) per share entitling holders to deferred cash payments of $10.00 per CVR upon FDA approval of Bylvay in the Biliary Atresia indication.
The acquisition is subject to regulatory approval and is expected to close with Ipsen's subsidiary initiating a tender offer to acquire all outstanding shares of ALBO.

Generated by AI

Community

Of the messages about ALBO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	10.64%
Newcomers	—	—	—	89.36%

Regulars· Mar 2

The $ALBO stock price is trading at $2.6, with a potential payout of $10 in a few years, making it seem cheap to some investors, and a Centerview valuation of $3.26.
Albireo Pharma has completed its acquisition or disposition of assets, as per its 8-K filing on March 2, and has requested that Nasdaq file a Form 25 Notification of Removal from Listing.
The RSI Indicator for $ALBO has left the overbought zone, and the stock is up 175% from its low, with a close price of $44.25 and a volume of 2.14, and a liquidation value of $84M.

Newcomers· Jan 9

The acquisition of Albireo Pharma by Ipsen is a significant event, with a potential deal value of $1.2 billion and a cash price of $42 per share.
The takeover has a positive impact on Mirum Pharmaceuticals, making it a potential takeover candidate, and also has a read-through to XFOR, which is now well-capitalized and has a high potential for growth.
The acquisition is expected to accelerate growth in rare diseases, with Ipsen gaining treatments for several pediatric liver diseases, and has a strong impact on Albireo's stock price, with a 85% jump.

Generated by AI

Also Discussed

Investors talking about ALBO also mention

#	Name	Attention
1	Mirum Pharmaceuticals, Inc.MIRM	0%0
2	DarioHealth Corp.DRIO	0%0
3	KALV - KalVista Pharmaceuticals, Inc.	——
4	BPMC - Blueprint Medicines Corporation	——
5	PRVB - Provention Bio, Inc.	——
6	MYOV - Myovant Sciences Ltd.	——
7	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0
8	MediWound Ltd.MDWD	0%0
9	ALPN - Alpine Immune Sciences, Inc.	——
10	SWTX - SpringWorks Therapeutics, Inc.	——

Albireo Pharma, Inc.

Location

Social

What share of all stock conversation is about ALBO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% new	0% 0

Apr 25

The $ALBO meme coin is now permanent on the Solana blockchain, making it impossible for the Australian PM to censor.
The coin is being used to support the Australian government in their legal battle, with some users donating a portion of their $ALBO holdings to the cause.
The $ALBO meme coin is expected to gain popularity in the next few weeks, with some users predicting it could become a top 10 material.

Generated by AI

Sentiment

Of the messages about ALBO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +20.83
Bearish	—	—	—	0% -20.83

Bullish· Jan 9

The acquisition of Albireo Pharma by Ipsen is a significant event with a potential buyout price of $42 per share, up from its previous closing price.
The buyout has a positive read-through to another company, XFOR, which has recently secured a $30m loan and is now well capitalized, potentially leading to a 3x-5x organic growth and 8x-10x on a buyout.
The Albireo Pharma acquisition is a great example of patience paying off in investing, with long-term holders able to secure a significant profit, and may lead to increased focus on other takeover candidates in the biotech industry.

Bearish· Aug 16

Albireo Pharma's stock price has dropped significantly, from a high of $42 to $18, due to poor commercialization efforts.
The company's sales costs are high, with a sales personnel cost increase of $6 million, and the sales force is inefficient, leading to missed sales targets.
Albireo Pharma's cash burn is a major concern, with a net loss of $40 million and a risk of running out of money in less than 6 months if the current burn rate continues.

Generated by AI

Topics

Of the messages about ALBO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	0%
Macro	—	—	—	0%
Earnings	—	—	—	0%
Controversies	—	—	—	0%
Announcements	—	—	—	100%
Analysts	—	—	—	0%

Earnings· Aug 7

Albireo Pharma, Inc. (ALBO) misses EPS loss estimates by $0.27.
Albireo Pharma, Inc. (ALBO) beats revenue estimates.
Albireo Pharma, Inc. (ALBO) announces earnings with an EPS of $1.22, missing estimates.

Analysts· Jan 11

Analysts have downgraded Albireo Pharma, with Cowen lowering the stock to Market Perform from Outperform and Jefferies downgrading to Hold from Buy.
Price targets have been lowered for Albireo Pharma, with Cowen setting a new target of $48 and Jefferies lowering its target to $42.
Multiple analysts, including those from Cowen, Jefferies, and Guggenheim, have downgraded Albireo Pharma, citing concerns about the company's prospects following Ipsen's proposed acquisition.

Announcements· Jan 10

Albireo Pharma, Inc. (ALBO) agreed to be acquired by Ipsen in a deal valued at $952 million, with shares jumping 92% to a new 52-week high.
The acquisition price of $42.00 per share will be paid in cash, with an additional contingent value right (CVR) per share entitling holders to deferred cash payments of $10.00 per CVR upon FDA approval of Bylvay in the Biliary Atresia indication.
The acquisition is subject to regulatory approval and is expected to close with Ipsen's subsidiary initiating a tender offer to acquire all outstanding shares of ALBO.

Generated by AI

Community

Of the messages about ALBO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	10.64%
Newcomers	—	—	—	89.36%

Regulars· Mar 2

The $ALBO stock price is trading at $2.6, with a potential payout of $10 in a few years, making it seem cheap to some investors, and a Centerview valuation of $3.26.
Albireo Pharma has completed its acquisition or disposition of assets, as per its 8-K filing on March 2, and has requested that Nasdaq file a Form 25 Notification of Removal from Listing.
The RSI Indicator for $ALBO has left the overbought zone, and the stock is up 175% from its low, with a close price of $44.25 and a volume of 2.14, and a liquidation value of $84M.

Newcomers· Jan 9

The acquisition of Albireo Pharma by Ipsen is a significant event, with a potential deal value of $1.2 billion and a cash price of $42 per share.
The takeover has a positive impact on Mirum Pharmaceuticals, making it a potential takeover candidate, and also has a read-through to XFOR, which is now well-capitalized and has a high potential for growth.
The acquisition is expected to accelerate growth in rare diseases, with Ipsen gaining treatments for several pediatric liver diseases, and has a strong impact on Albireo's stock price, with a 85% jump.

Generated by AI

Albireo Pharma

Social

Apr 25

Sentiment

Bullish· Jan 9

Bearish· Aug 16

Topics

Earnings· Aug 7

Analysts· Jan 11

Announcements· Jan 10

Community

Regulars· Mar 2

Newcomers· Jan 9

Also Discussed

Albireo Pharma, Inc.

Company Information

Location

Also Discussed

Social

Apr 25

Sentiment

Bullish· Jan 9

Bearish· Aug 16

Topics

Earnings· Aug 7

Analysts· Jan 11

Announcements· Jan 10

Community

Regulars· Mar 2

Newcomers· Jan 9